References
Adriani KS, Brouwer MC, Geldhoff M, Baas F, Zwinderman AH, Paul Morgan B, et al. (2013). Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. J Infect 66:255-262.
Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, et al. (2001). Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 166: 6341-6348.
An P, Saenz Robles MT, Duray AM, Cantalupo PG, & Pipas JM (2019). Human polyomavirus BKV infection of endothelial cells results in interferon pathway induction and persistence. PLoS Pathog 15: e1007505.
Antoniou K, Ender F, Vollbrandt T, Laumonnier Y, Rathmann F, Pasare C, et al. (2020). Allergen-Induced C5a/C5aR1 Axis Activation in Pulmonary CD11b(+) cDCs Promotes Pulmonary Tolerance through Downregulation of CD40. Cells 9.
Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, et al. (2016). T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science 352:aad1210.
Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, Kohl J, et al. (2013). C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122: 3473-3481.
Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, et al. (2009). Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 15: 1543-1554.
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. (2020). Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 217.
Belford A, Myles O, Magill A, Wang J, Myhand RC, & Waselenko JK (2004). Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation. Am J Hematol 76: 156-162.
Bernig T, Taylor JG, Foster CB, Staats B, Yeager M, & Chanock SJ (2004). Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes Immun 5: 461-476.
Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, et al.(2007). Studies on the interactions between C-reactive protein and complement proteins. Immunology 121: 40-50.
Bitzan M, & Zieg J (2018). Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 33: 2009-2025.
Borosss P, Yildiz C, Simons PJ, Boon L, & Hack CE (2016). A monoclonal antibody against complement C2 as a novel inhibitor. In Atlant Conference 2016:Innate Host Defence. Utrecht, The Netherlands.
Bouts A, Monnens L, Davin JC, Struijk G, & Spanjaard L (2011). Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 26: 1919-1920.
Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, et al. (2004). Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol 42:2629-2635.
Chen L, Li X, Chen M, Feng Y, & Xiong C (2020). The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res.
Chen S, Lu D, Zhang M, Che J, Yin Z, Zhang S, et al. (2005). Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum. Eur J Clin Microbiol Infect Dis 24: 549-553.
Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, et al. (2010). Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 42: 772-776.
Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. (2020). Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24: 4040-4047.
Dobo J, Szakacs D, Oroszlan G, Kortvely E, Kiss B, Boros E, et al. (2016). MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep 6: 31877.
Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E, et al. (2002). Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 99: 185-192.
Ekdahl KN, Mohlin C, Adler A, Aman A, Manivel VA, Sandholm K, et al. (2019). Is generation of C3(H2O) necessary for activation of the alternative pathway in real life? Mol Immunol 114: 353-361.
Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, et al. (2016). Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 274: 245-269.
el-Lati SG, Dahinden CA, & Church MK (1994). Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 102: 803-806.
Fischer WH, & Hugli TE (1997). Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 159: 4279-4286.
Fischer WH, Jagels MA, & Hugli TE (1999). Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 162: 453-459.
Fox SE, Akmatbekov A, Harbert JL, Li G, Brown Q, & Vander Heide RS (2020). Pulmonary and cardiac pathology in COVID-19: the first autopsy series from New Orleans: medRxiv.
Fukuoka Y, & Hugli TE (1988). Demonstration of a specific C3a receptor on guinea pig platelets. J Immunol 140: 3496-3501.
Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, et al. (2017). Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep 7: 1080.
Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. (2020). Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2.mediated complement over-activation. doi: doi: https://doi.org/10.1101/2020.03.29.20041962
Garcia CC, Weston-Davies W, Russo RC, Tavares LP, Rachid MA, Alves-Filho JC, et al. (2013). Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury. PLoS One 8: e64443.
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. (2011). Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3: 73ra20.
Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, et al. (2016). A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev 274: 74-97.
Garred P, J JS, Quist L, Taaning E, & Madsen HO (2003). Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188: 1394-1403.
Garred P, Larsen F, Seyfarth J, Fujita R, & Madsen HO (2006). Mannose-binding lectin and its genetic variants. Genes Immun 7:85-94.
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, & Chiumello D (2020). Covid-19 Does Not Lead to a ”Typical” Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med.
Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. (2020). Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe.
Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh R, et al. (2020). Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy. Biol Blood Marrow Transplant 26:S15-S16.
Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN, et al. (2017). Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 130: 1259-1266.
Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, & Christiani DC (2007). Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med 35: 48-56.
Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura JI, Nunn MA, et al. (2017). Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv 1: 1254-1258.
Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. (2018). Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 9.
Guan M, Chen HY, Foo SY, Tan YJ, Goh PY, & Wee SH (2004). Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients. Clin Diagn Lab Immunol 11: 287-291.
Guglietta S, Chiavelli A, Zagato E, Krieg C, Gandini S, Ravenda PS, et al. (2016). Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun 7: 11037.
Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, & Woodruff TM (2017). New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol 89: 36-43.
Hayashi M, Machida T, Ishida Y, Ogata Y, Omori T, Takasumi M, et al. (2019). Cutting Edge: Role of MASP-3 in the Physiological Activation of Factor D of the Alternative Complement Pathway. J Immunol 203: 1411-1416.
Hellemann D, Larsson A, Madsen HO, Bonde J, Jarlov JO, Wiis J, et al. (2007). Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum Mol Genet 16: 3071-3080.
Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendorf AM, Baensch M, et al. (1999). Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 163:985-994.
Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP, et al. (2011). Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 108:8761-8766.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. (2005). Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191: 1697-1704.
Jager U, D’Sa S, Schorgenhofer C, Bartko J, Derhaschnig U, Sillaber C, et al. (2019). Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 133: 893-901.
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. (2017). Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol 28:2756-2767.
Jiang Y, Li J, Teng Y, Sun H, Tian G, He L, et al. (2019). Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses 11.
Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, et al. (2018). Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect 7: 77.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, et al. (2016a). Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. Biol Blood Marrow Transplant 22: 1337-1340.
Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. (2020a). Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135:1049-1057.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al.(2014). Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124: 645-653.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. (2016b). Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22: 307-315.
Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, et al. (2020b). Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 4:1166-1177.
Jodele S, Zhang K, Dandoy CE, Myers KC, Lane A, & Davies SM (2017). Donor genotype and susceptibility to transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 03.
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al.(2016c). The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127:989-996.
Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, et al.(2016). Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol 23: 378-386.
Karasu E, Nilsson B, Kohl J, Lambris JD, & Huber-Lang M (2019). Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Front Immunol 10: 543.
Karsten CM, & Kohl J (2012). The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217:1067-1079.
Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, & Kohl J (2009). The role of the anaphylatoxins in health and disease. Mol Immunol 46: 2753-2766.
Kordowski A, Reinicke AT, Wu D, Orinska Z, Hagemann P, Huber-Lang M, et al. (2019). C5a receptor 1(-/-) mice are protected from the development of IgE-mediated experimental food allergy. Allergy 74: 767-779.
Kretzschmar T, Jeromin A, Gietz C, Bautsch W, Klos A, Kohl J, et al. (1993). Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur J Immunol 23: 558-561.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. (2019). Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133: 540-549.
Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S, et al. (2019). The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis.
Laumonnier Y, Karsten CM, & Kohl J (2017). Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol 89: 44-58.
Lazar HL, Keilani T, Fitzgerald CA, Shapira OM, Hunter CT, Shemin RJ, et al. (2007). Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 116: I83-88.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W, et al. (2019). Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133: 530-539.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. (2013). Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181.
Levi M, Cohn DM, & Zeerleder S (2019). Hereditary angioedema: Linking complement regulation to the coagulation system. Res Pract Thromb Haemost 3: 38-43.
Lipworth B, Chan R, Lipworth S, & RuiWen Kuo C (2020). Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J Allergy Clin Immunol Pract.
Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. (2020). Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol.
Lounder DT, Bin Q, de Min C, & Jordan MB (2019). Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv 3: 47-50.
Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et al. (1995). Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 155: 3013-3020.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. (2020). Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res.
Mastellos DC, Ricklin D, & Lambris JD (2019). Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 18: 707-729.
[Online] Available from https://clinicaltrials.gov/ct2/results?cond=Thrombotic+Microangiopathies&term=OMS721&cntry=&state=&city=&dist=&Search=Search. [Accessed: 042020 2020].
[Online] Available from https://www.clinicaltrials.gov/ct2/show/NCT03347396?term=NCT03347396&rank=1. [Accessed].
Meliopoulos VA, Karlsson EA, Kercher L, Cline T, Freiden P, Duan S, et al. (2014). Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism. J Virol 88:12982-12991.
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. (2014). Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370: 632-639.
Ohta R, Torii Y, Imai M, Kimura H, Okada N, & Ito Y (2011). Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 55: 191-198.
Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL, et al.(2004). C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem 279: 142-151.
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11: 1620.
Paun CC, Lechanteur YTE, Groenewoud JMM, Altay L, Schick T, Daha MR, et al. (2016). A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo. Sci Rep 6: 26568.
Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al.(2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.
Reid RC, Yau MK, Singh R, Hamidon JK, Reed AN, Chu P, et al.(2013). Downsizing a human inflammatory protein to a small molecule with equal potency and functionality. Nat Commun 4: 2802.
Ricklin D, Mastellos DC, Reis ES, & Lambris JD (2018). The renaissance of complement therapeutics. Nat Rev Nephrol 14: 26-47.
Ricklin D, Reis ES, Mastellos DC, Gros P, & Lambris JD (2016). Complement component C3 - The ”Swiss Army Knife” of innate immunity and host defense. Immunol Rev 274: 33-58.
Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, et al. (2012). The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119:6307-6316.
Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, et al. (2008). Functional roles for C5a receptors in sepsis. Nat Med 14: 551-557.
Rowley JA, Reid RC, Poon EKY, Wu KC, Lim J, Lohman RJ, et al.(2020). Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity. J Med Chem 63: 529-541.
Sahu A, Kay BK, & Lambris JD (1996). Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 157: 884-891.
Schindler R, Gelfand JA, & Dinarello CA (1990). Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76: 1631-1638.
Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, et al. (2013). Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 190: 5712-5721.
Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. (2020). Proteomic and Metabolomic characterization of COVID-19 patient sera. doi: doi: https://doi.org/10.1101/2020.04.07.20054585
Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et al. (2014). TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 123:4015-4022.
Steffensen R, Thiel S, Varming K, Jersild C, & Jensenius JC (2000). Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 241: 33-42.
Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, & Bemelman FJ (2013). Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 13: 819-820.
Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, et al. (2015). Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis 60:586-595.
Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, et al. (2013). Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol 49: 221-230.
Thye T, Niemann S, Walter K, Homolka S, Intemann CD, Chinbuah MA, et al. (2011). Variant G57E of mannose binding lectin associated with protection against tuberculosis caused by Mycobacterium africanum but not by M. tuberculosis. PLoS One 6: e20908.
Tu X, Chong WP, Zhai Y, Zhang H, Zhang F, Wang S, et al. (2015). Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect 71: 101-109.
Umemura M, Miwa Y, Yanai R, Isojima S, Tokunaga T, Tsukamoto H, et al. (2015). A case of Degos disease: demonstration of C5b-9-mediated vascular injury. Mod Rheumatol 25: 480-483.
[Online] Available from https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. [Accessed].
Vallurupalli M, & Berliner N (2019). Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood 134: 1783-1786.
Wang R, Xiao H, Guo R, Li Y, & Shen B (2015). The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect 4: e28.
Weaver DJ, Jr., Reis ES, Pandey MK, Kohl G, Harris N, Gerard C, et al. (2010). C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 40: 710-721.
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8: 420-422.
Yabe H, Hattori K, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, et al. (2005). Fatal adenovirus infection indistinguishable from thrombotic microangiopathy after allogeneic CD34+ peripheral progenitor cell transplantation. Tokai J Exp Clin Med 30: 71-75.
Yuan FF, Tanner J, Chan PK, Biffin S, Dyer WB, Geczy AF, et al.(2005). Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome. Tissue Antigens 66: 291-296.
Yuen J, Pluthero FG, Douda DN, Riedl M, Cherry A, Ulanova M, et al. (2016). NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol 7: 137.
Zareei N, Miri HR, Karimi MH, Afshari A, Geramizadeh B, Roozbeh J, et al. (2019). Increasing of the interferon-gamma gene expression during polyomavirus BK infection in kidney transplant patients. Microb Pathog 129: 187-194.
Zhang H, Zhou G, Zhi L, Yang H, Zhai Y, Dong X, et al. (2005). Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 192: 1355-1361.
Zhao M (2020). Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents: 105982.
Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, et al. (2010). A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 84: 8753-8764.